Floatz logo

Panitumumab-Irdye800

Acoustic Neuroma

Eben RosenthalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Acoustic Neuroma cohort.

Asset / SponsorPhaseRating
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
rg4733
National Cancer Institute (NCI)
Phase 1C

Same molecule, other indications

Panitumumab-Irdye800 is also rated in:

pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
meningiomaDormant
C
Indicative ·
39 / 100
View asset →
brain cancerDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →